Programmed Co-delivery of tamoxifen and docetaxel using lipid-coated mesoporous silica nanoparticles for overcoming CYP3A4-mediated resistance in triple-negative breast cancer treatment

This study aims to revolutionize the treatment of aggressive triple-negative breast cancer (TNBC), notorious for its resistance to standard therapies. By ingeniously combining Tamoxifen (TMX) and Docetaxel (DTX) within a lipid-coated mesoporous silica nanoparticle (LP-MSN) delivery system, we intend...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biomedicine & pharmacotherapy 2024-01, Vol.170, p.116084-116084, Article 116084
Hauptverfasser:	Wang, Yinan, Cheng, WeiYi, Zhu, Jingjing, He, Li, Ren, WeiYe, Bao, Dandan, Piao, Ji-Gang
Format:	Artikel
Sprache:	eng
Schlagworte:	Docetaxel Drug combination Lipid-coated mesoporous silica nanoparticles Tamoxifen Triple-negative breast cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!